KRAS status analysis and anti-EGFR therapies: Is comprehensiveness a biologist's fancy or a clinical necessity

British Journal of Cancer

Volumn 102, Issue 6, 2010, Pages 1074-1075

  Lopez Crapez, E ^a   Mineur, L ^b   Emptas, H ^c   Lamy, P J ^a  

^a CENTRE VAL D AURELLE   (France)

^b Sainte Catherine Institute   (France)

^c Pathology Laboratory   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IRINOTECAN; K RAS PROTEIN; PROTEIN;

AMINO ACID SUBSTITUTION; CANCER STAGING; CLINICAL TRIAL; COLORECTAL METASTASIS; DRUG EFFECT; GENE INSERTION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; LETTER; METASTASIS; MISSENSE MUTATION; PRIORITY JOURNAL; SOMATIC MUTATION;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; GENES, RAS; HUMANS; MALE; MEDICAL FUTILITY; MUTATION; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77949542415     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605582     Document Type: Letter

References (13)

1. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634
2. Bollag G, Adler F, elMasry N, McCabe PC, Conner Jr E, Thompson P, McCormick F, Shannon K (1996) Biochemical characterization of a novel KRAS insertion mutation from a human leukemia. J Biol Chem 271: 32491-32494
3. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboüé R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96: 1166-1169
4. Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, Cole C, Kok CY, Jia M, Ewing R, Menzies A, Teague JW, Stratton MR, Futreal PA (2009) COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res 38(database issue): D652-D657
5. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG (2009) KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 27: 1130-1136
6. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765
7. Klockow B, Ahmadian MR, Block C, Wittinghofer A (2000) Oncogenic insertional mutations in the P-loop of Ras are overactive in MAP kinase signaling. Oncogene 19: 5367-5376
8. Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM (2008) Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med 14: 579-584
9. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379
10. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F (2009) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 101: 715-721
11. Malumbres M, Barbacid M (2003) RAS oncogenes: the first 30 years. Nat Rev Cancer 3: 459-465
12. Simi L, Pratesi N, Vignoli M, Sestini R, Cianchi F, Valanzano R, Nobili S, Mini E, Pazzagli M, Orlando C (2008) High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 130: 247-253
13. Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, Pryor RJ (2003) High-resolution genotyping by amplicon melting analysis using LCGreen. Clin Chem 49: 853-860